CÁC YẾU TỐ TIÊN LƯỢNG TRONG ĐIỀU TRỊ UNG THƯ BÀNG QUANG NÔNG BẰNG BCG NỘI BÀNG QUANG TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate prognostic factors in patients with non–muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin at Vietnam National Cancer Hospital. Patients and Research Method: A cross-sectional descriptive study was conducted on 82 newly diagnosed NMIBC patients who underwent transurethral resection of bladder tumors (TURBT) and received adjuvant intravesical BCG therapy at Vietnam National Cancer Hospital from April 2015 to December 2020. Estimated recurrence-free survival time according to the Kalpan-Meier method. Analyze factors affecting recurrence-free survival using the Cox regression method with 95% confidence (p=0,05). Results: The survival rate without disease recurrence in the first 12 months was 90,2%. At 24 months this rate was 87,8%. At 36 months, the disease recurrence-free survival rate was 86,6%. After 48 months, the disease recurrence-free survival rate was 85,3% and maintained until the end of follow-up. Factors such as a multifocal tumor, histological grade, and BCG dosage are independent prognostic factors affecting the risk of disease recurrence. Conclusion: Adjuvant immunotherapy with intravesical BCG is highly effective in patients with superficial bladder cancer who have undergone laparoscopic tumor resection, helping to reduce the rate of recurrence and progression. Multifocal tumor, histological grade, and BCG dosage are independent prognostic factors affecting the risk of disease recurrence.